The National Comprehensive Cancer Network updated pancreatic adenocarcinoma guidelines to recommend tumor molecular profiling, preferably by DNA and RNA next‑generation sequencing (NGS), to detect actionable mutations and fusions. The guidance endorses ctDNA when tissue is unavailable and highlights tumor profiling’s role in identifying targeted therapy options. The change potentially redirects tens of thousands of patients toward molecular diagnostics vendors and lab networks, with payers and pathology labs facing implementation and reimbursement decisions. Companies that provide broad DNA/RNA testing and comprehensive reporting stand to gain early‑stage adoption in pancreatic oncology workflows.